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Abstract
Globally, in 2017 35 million people were living with HIV (PLHIV) and 257 million 
had chronic HBV infection (HBsAg positive). The extent of HIV-HBsAg co-infection 
is unknown. We undertook a systematic review to estimate the global burden of 
HBsAg co-infection in PLHIV. We searched MEDLINE, Embase and other databases 
for published studies (2002-2018) measuring prevalence of HBsAg among PLHIV. 
The review was registered with PROSPERO (#CRD42019123388). Populations were 
categorized by HIV-exposure category. The global burden of co-infection was esti-
mated by applying regional co-infection prevalence estimates to UNAIDS estimates 
of PLHIV. We conducted a meta-analysis to estimate the odds of HBsAg among 
PLHIV compared to HIV-negative individuals. We identified 506 estimates (475 stud-
ies) of HIV-HBsAg co-infection prevalence from 80/195 (41.0%) countries. Globally, 
the prevalence of HIV-HBsAg co-infection is 7.6% (IQR 5.6%-12.1%) in PLHIV, or 2.7 
million HIV-HBsAg co-infections (IQR 2.0-4.2). The greatest burden (69% of cases; 
1.9 million) is in sub-Saharan Africa. Globally, there was little difference in preva-
lence of HIV-HBsAg co-infection by population group (approximately 6%-7%), but it 
was slightly higher among people who inject drugs (11.8% IQR 6.0%-16.9%). Odds 
of HBsAg infection were 1.4 times higher among PLHIV compared to HIV-negative 
individuals. There is therefore, a high global burden of HIV-HBsAg co-infection, es-
pecially in sub-Saharan Africa. Key prevention strategies include infant HBV vaccina-
tion, including a timely birth-dose. Findings also highlight the importance of targeting 
PLHIV, especially high-risk groups for testing, catch-up HBV vaccination and other 
preventative interventions. The global scale-up of antiretroviral therapy (ART) for 
PLHIV using a tenofovir-based ART regimen provides an opportunity to simulta-
neously treat those with HBV co-infection, and in pregnant women to also reduce 
mother-to-child transmission of HBV alongside HIV.
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1  | INTRODUC TION
Chronic hepatitis B (CHB) infection, defined as persistence of hepatitis B 
surface antigen (HBsAg), is a major public health problem resulting in an 
estimated 900 000 deaths in 2015.1-4 Although HBV can be prevented 
with vaccination, in 2015, there were an estimated 257 million persons 
chronically infected.4 Between 20 and 30% of those with chronic in-
fection develop complications, mainly cirrhosis and hepatocellular car-
cinoma (HCC).5 CHB accounts for 43% of cases of HCC and 40% of 
cirrhosis, with much higher proportions in lower middle-income coun-
tries,4 and 5%-10% of liver transplants in high-income countries.6 Age is 
a key determinant of the risk of chronic infection: chronicity is common 
following acute infection in neonates (around 90%) and young children 
under the age of 5 years (20–60%), but occurs rarely (<5%) when in-
fection is acquired in adulthood.7,8 Worldwide, most persons with CHB 
were infected at birth or in early childhood.9 The highest prevalence of 
HBsAg (>5%) is in sub-Saharan Africa, East Asia, parts of Balkans, the 
Pacific Islands and the Amazon Basin.10 Regional variation exists in the 
epidemiology of HBV: perinatal or horizontal transmission predomi-
nates in sub-Saharan Africa and Asia, whereas in high-income countries 
transmission is predominantly via injection drug use and high-risk sexual 
behaviours.9,11
As PLHIV live longer due to increased access to antiretroviral 
therapies, liver disease has emerged as a leading cause of death 
in PLHIV co-infected with HBV or HCV.12,13 Among people with 
HBsAg, co-infection with HIV results in higher rates of chronicity 
and occult HBV (HBV-DNA positivity in the absence of HBsAg), 
accelerated liver disease progression, higher liver-related mortality 
and decreased treatment response.14-17 Co-infection with CHB also 
increases risk of hepatotoxicity from antiretroviral therapy (ART) 
three- to five-fold,18,19 and cross-resistance between HIV and HBV 
drugs is common.20,21 Fortunately, tenofovir, a drug commonly in-
cluded in ART regimens, is also the most effective drug for long-
term treatment of HBV, leading to long-term HBV viral suppression, 
reversal of cirrhosis and fibrosis, and reduction in HBV-related 
mortality.22
There is a need to establish the global burden of HBsAg co-infec-
tion among PLHIV, to characterize the most affected populations and 
geographical regions, and to inform national and regional screening 
programmes and clinical management. However, to date, no review 
has estimated the global burden of HBV co-infection among PLHIV. 
Existing estimates suggest approximately 10% of PLHIV have chronic 
hepatitis B or 2-4 million people, but were based on small numbers 
of studies with unclear methodology.17,23,24 Other reviews have fo-
cussed on specific regions25 or people who inject drugs (PWID).11,26 
We therefore undertook a global systematic review of the prevalence 
and burden of HBsAg in PLHIV.
2  | METHODS
2.1 | Search strategy and selection criteria
The systematic review was conducted alongside a companion review 
examining prevalence and burden of HIV-HCV antibody co-infection 
(consistent with current or past infection) which contains detailed 
description of the search and synthesis methods.27 The review was 
registered with the PROSPERO prospective register of systematic 
reviews (CRD42019123388).
In brief, we searched eight databases for material that reported 
prevalence of HBV and HIV, published between 1 January 2002 
and 8 April 2018 following PRISMA guidelines.28 The searches 
were carried out in MEDLINE, EMBASE, CINAHL+, POPLINE, 
Africa-wide Information, Global Health, Web of Science, and the 
Cochrane Library, Index Medicus of the Eastern Mediterranean 
Region, Index Medicus of the South-East Asian Region, LILACS and 
Western Pacific Region Index Medicus. All English and non-English 
language sources were included. The search terms used were as 
follows: ‘HIV OR Human immunodeficiency virus’ and ‘hepatitis-B 
OR hepatitis C OR HBV OR HCV’ and ‘prevalen* OR inciden* OR 
seroprevalen* OR screening OR surveillance OR population* OR 
survey* OR epidem* OR data collection OR population sample* OR 
community survey* OR cohort OR cross-sectional OR longitud* 
OR follow-up’. Searches were tailored to the search functionality 
of each database. The reference lists of articles identified as re-
views were screened for additional relevant sources.
We included papers with country-level estimates of HBsAg 
co-infection among an HIV population sample greater than 50, re-
cruited based on their HIV-positive status or other behavioural 
characteristics, such as injecting drug use. We excluded editorials 
or reviews containing no primary data, samples recruited based on 
their HBsAg status or HIV-HBsAg-positive status; studies based 
on self-reported HIV or HBsAg status, hospital-based studies, or 
in healthcare workers, organ or tissue donors, or from populations 
with other co-morbidities such as persons with TB or mental illness, 
or undergoing interventions that put them at greater risk of co-in-
fection, including those receiving haemodialysis, those with haemo-
philia, cancer, cardiovascular disease, other co-infections, kidney, 
liver or neurological diseases.
2.2 | Screening and data extraction
Six reviewers (CF, CM, BM, AT, JS and JO) screened each record with 
a seventh reviewer (LP) consulted when there was no consensus. 
Data extracted included the following: study methods; field-work 
K E Y W O R D S
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dates; population; recruitment site; sample size; diagnostic assays 
used; and prevalence of co-infection. For approximately 10% of in-
cluded studies, data were double extracted by a second author (EG) 
to check the accuracy of data extraction.
2.3 | Quality assessment
To address concerns of variable quality of studies in previous reviews, 
we assessed and rated the quality of included studies based on study 
design and assay quality (Supporting information S1). Studies with 
larger sample sizes, recruited from multiple sites, recording age and 
sex or HIV risk factors were scored higher (A); studies with >200 cases 
from >1 site, with some HIV risk factors recorded but not designed to 
measure prevalence was scored lower (B); and studies with <200 case 
from a single site with no risk factors recorded were scored lowest 
(C). HBsAg assay methods were rated from 0 where no assay type 
was specified, to up to 3 where a second confirmatory HBsAg assay 
was done, with or without a neutralisation step. Best estimates were 
selected for each population group per country based on the highest 
assay and study design score. Where multiple estimates were avail-
able, we applied decision rules to select the best estimate (Supporting 
information S1).
2.4 | Classification of countries according to Global 
Burden of Disease region
Countries were initially grouped according to the 21 Global Burden 
of Disease regions, and these were then combined into ten regions 
to be consistent with previous published reviews on HIV, HBsAg and 
HCV burden.11,27,29
2.5 | Definition of Population groups
We extracted data on risk behaviours associated with HIV and 
HBV transmission and populations were categorized according to 
their main HIV-exposure categories. A general population sam-
ple was considered to be low-risk and included samples of blood 
donors (unpaid), ante-natal clinic attendees or general population 
and household surveys not recruited based on HIV-positive sta-
tus. Samples of PLHIV reporting heterosexual transmission as the 
main risk factor and HIV-positive pregnant women were grouped 
together. We categorized study populations as PWID when >75% 
of the sample had current or past experience of injecting, and as 
men who have sex with men (MSM) when >50% reported main HIV 
exposure to be sex with men. The PWID and MSM population cat-
egories included studies of both known PLHIV as well as popula-
tions recruited based on their risk behaviour but where HIV testing 
was also done. Two other population groups included the follow-
ing: high-risk populations (PLHIV reporting any injecting drug use 
or sex between men (but ≤75% of the sample for PWID and ≤50% 
for MSM), sex workers; prison inmates, non-injecting drug users, 
STI clinic attendees or a mixed population engaging in sexual and/
or injecting risk behaviours but with ≤75% of the sample inject-
ing); and children and young people (aged between two months 
and 17 years).
2.6 | Data synthesis
We report HIV-HBsAg co-infection prevalence among six popu-
lation groups (general population, heterosexual and pregnant 
women, PWID, MSM, children and young people, and other 
high-risk populations) by country and region, reporting the best 
estimate and range for each country from all studies. Global and 
regional estimates of prevalence were derived from the median of 
the ‘best’ estimates for that region and presented alongside the 
interquartile range (IQR) of the best estimates. Data were entered 
into R (R Foundation for Statistical Computing, Vienna, Austria) 
to generate maps presenting country-level HIV-HBV co-infection 
prevalence estimates.
Across these six populations, we also synthesized estimates of 
HBsAg prevalence in PLHIV and HIV-negative populations where 
samples were recruited based on population characteristic rather 
than known HIV status and undertook a meta-analysis of the odds 
of being HBsAg positive among HIV-positive populations compared 
to HIV-negative populations stratified by population group. A stan-
dard correction of 0.5 was added to all zero prevalence estimates 
using STATA 14.1 (Stata Corp). Odds ratios were calculated through 
a Mantel-Haenszel method with a random-effect model. Meta-
analyses of sub-groups are presented as forest plots including the 
odds ratio and 95% confidence interval (CI).
Finally, we report global and regional estimates of burden of HBsAg 
co-infection among PLHIV in 2017. Using number of persons with 
HIV infection by country and region estimated through the Spectrum 
model and reported by the Joint United Nations Programmes on HIV/
AIDS (UNAIDS),30,31 we applied median best estimates of HBsAg 
co-infection prevalence among PLHIV not exposed via injecting drug 
use from all surveys included from the literature search for MSM, gen-
eral population and HIV-positive samples of pregnant women or those 
heterosexually exposed by regions, and overall. Median best estimates 
of HBsAg co-infection prevalence among HIV-positive PWID were ap-
plied to the distribution of PLHIV exposed via injecting drug use, as 
estimated by UNODC, across regions and overall.
2.7 | Role of the funding source
The WHO commissioned this review for the purpose of inform-
ing the update of the WHO guidelines on testing for viral hepa-
titis.22,23 The funder contributed to the data collection, analysis, 
interpretation and writing of the review. All authors had full access 
to the study data and share final responsibility for the findings 
submitted for publication. The full dataset and statistical source 
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code used to generate estimates and select best estimates is avail-
able from the corresponding author on request.
3  | RESULTS
Figure 1 summarizes the flow chart for the identification and selection 
of studies. From an overall 44 547 publication references, 475 papers/
studies met the inclusion criteria resulting in 506 estimates of the 
prevalence of HIV-HBsAg co-infection across six population groups 
(general populations, PLHIV heterosexual and pregnant women, 
PWID, MSM, other high-risk populations and children).
3.1 | Availability of studies and estimates by 
region and population group
Overall, 80 (41.0%) of 195 countries had estimates. One-third (n = 28) 
of these countries were from sub-Saharan Africa and 26.3% (n = 21) 
from Western/Central/Eastern Europe, with these regions having the 
highest proportion of countries with data (28/45 62.2% and 21/54 
38.9%, respectively). The number and proportion of countries with es-
timates from other regions were as follows: North Africa and Middle 
East (7/21 33.3%); Latin America (9/36 25.0%); East Asia (2/2 100%); 
South and South-East Asia (8/18 44.4%); Asia Pacific and Australasia 
(3/17 17.6%); and North America (2/2 100%).
Of the 506 co-infection prevalence estimates, 45 were from 
general population samples (8.9% of estimates), 90 from PLHIV 
populations who were either pregnant women or where heterosex-
ual transmission was the primary exposure (17.8% of estimates), 36 
among PWID (7.1%), 70 among MSM (13.8%), 22 among children 
and young people, and 243 (48.0%) from high-risk populations (202 
from mixed PWID and MSM populations, five among sex workers, 
seven among prisoners and 29 from other high-risk populations).
3.2 | Rating of study quality and assay method
Very few estimates were rated ‘A’ in study design quality (15/506), 
based on large multisite surveys. 63.8% (323/506) of studies were 
rated ‘B’ in study design quality, based on data from more than one 
site with a sample size >200, and 33.2% as ‘C’ (168/506). Two-fifths 
(n = 207) of estimates provided no information on type of HBsAg assay 
(rated 0), 23 estimates were based on a rapid test (rated 1), 218 used 
an HBsAg assay (any generation) with no confirmatory HBsAg assay 
(rated 2), and the remaining 58 used an HBsAg assay (any generation) 
with a confirmatory HBsAg assay (rated 3). Taking both assay and 
study design together, the highest rated study was among PWID in 
Vietnam33 (rated A3), with five studies (1.0%) having the next high-
est rating (A2). Most estimates were categorized as B0 (28.1%), B2 
(27.3%), followed by C2 (14.8%) and C0 (11.1%). This information is 
summarized in Table S2.
F I G U R E  1   Flow chart of included 
studies
(n = 2643)
(n = 475)
(n = 506)
-
(n = 202)
(n = 97)
(n = 30)
(n = 371)
(n = 6)
(n = 100)
Sample of HIV-HBsAg individuals
(n = 143)
article (n = 59)
n = <50 (130)
(n = 150)
(n = 880)
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3.3 | Prevalence of HIV-HBsAg co-infection by 
population group
3.3.1 | General population samples
The mid-point prevalence of HBsAg co-infection among 45 general 
population samples testing positive for HIV was 7.4% (IQR 1.4%-
15.7%) with country-level prevalence estimates shown in Figure 2A. 
The highest prevalence was from West and Central Africa at 16.4% 
compared to 4.4% and 8.8% from South and East Africa, respectively. 
Very low prevalence was reported from East Asia (0.4%, one study) and 
Latin America (0.9%). There were no general population studies from 
Europe, North America or Asia Pacific/Australasia. All estimates are 
summarized in Table 1 with global prevalence maps shown in Figure 2.
3.3.2 | Heterosexual and pregnant women
The mid-point prevalence of HBsAg co-infection among 90 stud-
ies in PLHIV heterosexual or pregnant women was 6.1% (IQR 3.4%-
11.0%) with country-level prevalence estimates shown in Figure 2B. 
Prevalence was higher in East Asia (12.8%, one study), West and 
Central Africa (12.0%), and lowest in Latin America (2.8%), North 
Africa and the Middle East (3.4%) and North America (4.2%). Among 
F I G U R E  2   Best estimates of hepatitis B Surface Antigen co-infection prevalence among samples of A, General population B, 
Heterosexual and pregnant women. C, People who inject drugs; D, Men who have sex with men; and E, Other high-risk individuals.
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TA B L E  1   Summary of global HIV-HBsAg co-infection prevalence estimate in general population sample, heterosexual and pregnant  
PLHIV, PWID and MSM
 General Population Heterosexual and pregnant women PWID MSM
 Total studies Best estimate Total studies Best estimate Total studies Best estimate Total studies Best estimate
Country n Rangeb  % S n Year n Rangeb  % S n Year n Rangeb  % S n Year N Rangeb  % S n Year  
West and Central Africa
Burkina Faso68-70 2 0.5-17.0 17.0 B3 761 2010 1 6.1 6.1 C3 115 2009              
Cameroon71-78 2 4.2-17.3 17.3 B3 301 2013 6c  8.3-14.6 11.8 B3 212 2010              
Cote D'Ivoire79,80       2c  9.0-12.7 12.7 C2 495 2006              
Congo81       1 7.7 7.7 B2 209 2008              
Equatorial Guinea82 1 15.7 15.7 B3 230 2013                    
Gambia83       1 12.2 12.2 C0 572 2009              
Ghana84-89 4 2.4-18.7 6.0 C2 168 2007 2 10.8-11.0 11.0 C2 155 2010              
Guinea-Bissau90       1 16 16.0 B1 576 2011              
Mali91,92 1 25.3 25.3 C2 518 2002 1 22 22.0 B2 242 2004              
Nigeria93-112 8 0.0-19.8 1.3 B2 174 2016 12c  2.0-11.9 4.2 B2 2391 2011              
Senegal113       1 16.8 16.8 C2 363 2002              
Totala  18 6.0-17.3 16.4    28 7.7-16.0 12.0                 
South Africa
Botswana114,115       2 0.0-5.3 0.0 B2 1995 2006              
Lesotho116       1 5.5 5.5 B2 205 2007              
South Africa117-122 1 7.4 7.4 B3 215 2009 5c  2.1-7.4 7.4 B3 189 2013              
Zimbabwe123 1 1.4 1.4 C2 74 2005                    
Totala  2 1.4-7.4 4.4    8 0.0-7.4 5.5                 
East Africa
Comoros124       1 8 8.0 C0 50 2002              
Djibouti125 1 9.7 9.7 C3 175 2000                    
Ethiopia126-133 4 0.7-61.4 7.9 B2 101 2013 4 3.0-6.1 5.0 C3 400 2011              
Kenya36,134-138 1 20.9 6.8 B1 267 2007 4 5.2-6.9 6.1 B2 378 2007 1 13.9 13.9 C2 72 2010        
Malawi139-141       3c  5.0-16.9 8.7 C3 309 2009              
Mozambique142,143 2 10.1-13.8 13.8 C0 58 2009                    
Rwanda144,145 1 5.7 5.7 C2 384 2001 1c  2.4 2.4 C3 85 2004              
Tanzania146,147       1c  6.2 6.2 C0 17 539 2011       1 9.2 9.2 B0 65 2007  
Uganda145,148-152 4 4.6-8.3 6.0 B2 72 1999 2c  4.6-4.9 4.9 C3 164 2004              
Zambia153       1 9.9 9.9 C2 323 2008              
Totala  13 6.0-13.8 8.8    17 4.9-8.4 6.1    1 13.9 13.9    1 9.2 9.2     
N Africa & Middle East
Egypt154 1 3.4 3.4 C2 59 2015                    
Iran (Islamic Republic 
of)35,155-158
            5 2.1-44.2 2.1 B3 888 2007        
Lebanon                          
Libya159             1 5.1 5.1 B0 294 2010        
Morocco160       1c  2.4 2.4 C2 1120 2015              
Saudi Arabia161       1 3.4 3.4 C1 234 2010              
Sudan162,163       2 11.7-14.5 11.7 B3 358 2012              
Totala  1 3.4 3.4    4 2.4-11.7 3.4    6 2.1-5.1 3.6           
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(Continues)
TA B L E  1   Summary of global HIV-HBsAg co-infection prevalence estimate in general population sample, heterosexual and pregnant  
PLHIV, PWID and MSM
 General Population Heterosexual and pregnant women PWID MSM
 Total studies Best estimate Total studies Best estimate Total studies Best estimate Total studies Best estimate
Country n Rangeb  % S n Year n Rangeb  % S n Year n Rangeb  % S n Year N Rangeb  % S n Year  
West and Central Africa
Burkina Faso68-70 2 0.5-17.0 17.0 B3 761 2010 1 6.1 6.1 C3 115 2009              
Cameroon71-78 2 4.2-17.3 17.3 B3 301 2013 6c  8.3-14.6 11.8 B3 212 2010              
Cote D'Ivoire79,80       2c  9.0-12.7 12.7 C2 495 2006              
Congo81       1 7.7 7.7 B2 209 2008              
Equatorial Guinea82 1 15.7 15.7 B3 230 2013                    
Gambia83       1 12.2 12.2 C0 572 2009              
Ghana84-89 4 2.4-18.7 6.0 C2 168 2007 2 10.8-11.0 11.0 C2 155 2010              
Guinea-Bissau90       1 16 16.0 B1 576 2011              
Mali91,92 1 25.3 25.3 C2 518 2002 1 22 22.0 B2 242 2004              
Nigeria93-112 8 0.0-19.8 1.3 B2 174 2016 12c  2.0-11.9 4.2 B2 2391 2011              
Senegal113       1 16.8 16.8 C2 363 2002              
Totala  18 6.0-17.3 16.4    28 7.7-16.0 12.0                 
South Africa
Botswana114,115       2 0.0-5.3 0.0 B2 1995 2006              
Lesotho116       1 5.5 5.5 B2 205 2007              
South Africa117-122 1 7.4 7.4 B3 215 2009 5c  2.1-7.4 7.4 B3 189 2013              
Zimbabwe123 1 1.4 1.4 C2 74 2005                    
Totala  2 1.4-7.4 4.4    8 0.0-7.4 5.5                 
East Africa
Comoros124       1 8 8.0 C0 50 2002              
Djibouti125 1 9.7 9.7 C3 175 2000                    
Ethiopia126-133 4 0.7-61.4 7.9 B2 101 2013 4 3.0-6.1 5.0 C3 400 2011              
Kenya36,134-138 1 20.9 6.8 B1 267 2007 4 5.2-6.9 6.1 B2 378 2007 1 13.9 13.9 C2 72 2010        
Malawi139-141       3c  5.0-16.9 8.7 C3 309 2009              
Mozambique142,143 2 10.1-13.8 13.8 C0 58 2009                    
Rwanda144,145 1 5.7 5.7 C2 384 2001 1c  2.4 2.4 C3 85 2004              
Tanzania146,147       1c  6.2 6.2 C0 17 539 2011       1 9.2 9.2 B0 65 2007  
Uganda145,148-152 4 4.6-8.3 6.0 B2 72 1999 2c  4.6-4.9 4.9 C3 164 2004              
Zambia153       1 9.9 9.9 C2 323 2008              
Totala  13 6.0-13.8 8.8    17 4.9-8.4 6.1    1 13.9 13.9    1 9.2 9.2     
N Africa & Middle East
Egypt154 1 3.4 3.4 C2 59 2015                    
Iran (Islamic Republic 
of)35,155-158
            5 2.1-44.2 2.1 B3 888 2007        
Lebanon                          
Libya159             1 5.1 5.1 B0 294 2010        
Morocco160       1c  2.4 2.4 C2 1120 2015              
Saudi Arabia161       1 3.4 3.4 C1 234 2010              
Sudan162,163       2 11.7-14.5 11.7 B3 358 2012              
Totala  1 3.4 3.4    4 2.4-11.7 3.4    6 2.1-5.1 3.6           
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 General Population Heterosexual and pregnant women PWID MSM
 Total studies Best estimate Total studies Best estimate Total studies Best estimate Total studies Best estimate
Country n Rangeb  % S n Year n Rangeb  % S n Year n Rangeb  % S n Year N Rangeb  % S n Year  
West, Central and East Europe
Belgium164,165                   3 0.0-6.1 6.1 B0 3081 2009  
Bulgaria166             1 16.9 16.9 B2 359 2011 1 9.7 9.7 B2 1087 2011  
Denmark                          
France167-171       2c  6.0-6.9 6.9 B0 6548 2013       2 5.0-8.8 8.8 B2 2351 2002  
Georgia                          
Germany169,172-174                   4 1.7-25.4 25.4 B3 1843 2012  
Greece175,176                   2 6.0-6.5 6.0 A2 1729 2003  
Ireland                          
Italy177,178             2 3.5-7.0 7.0 C2 173 2006        
Moldova             1 11.0 11.0 C3 113 2009        
Netherlands179-182       1c  4.9 4.9 B0 1546 2008       2 5.2-7.7 5.2 A2 12 800 2012  
Poland                          
Portugal183             1 4.1 4.1 C0 343 2005        
Romania                          
Spain184-188       1 2.3 2.3 B0 741 2006 1 3.9 3.9 B0 821 2015 4 4.3-10.9 4.3 B2 392 2011  
Serbia                          
Slovenia                          
Switzerland                          
Turkey189-191       2 7.1-11.4 11.4 C3 70 2007       1 4.0-4.0 4.0 B0 55 2009  
United Kingdom192,193                   2 2.1-5.3 5.3 A0 25 486 2012  
Ukraine                          
Totala        6 4.9-7.1 5.9    6 4.1-11.0 7.0    21 5.2-8.8 6.0     
East Asia
China34,194-199 1 0.4 0.4 C0 275 2017       5 1.1-59.6 11.8 B3 498 2014 1 14.2-14.2 14.2 B0 532 2010  
China, province of 
Taiwan200-217
      1 12.8 12.8 B2 105 2005 6 17.4-20.0 18.9 A2 301 2010 13 3.5-22.0 3.5 C3 523 2012  
Totala  1 0.4 0.4    1 12.8 12.8    11 11.8-18.9 15.4    14 3.5-14.2 8.8     
South and South-East Asia
Cambodia                          
India218-235 6 0.0-8.3 8.3 B2 121 2017 8 0.0-7.1 3.4 B2 3142 2012 2 11.9-12.9 12.9 B2 595 2014 2 3.2-7.9 7.9 B2 1178 2002  
Indonesia236,237             2 7.0-17.6 17.6 B3 74 2009        
Malaysia                          
Myanmar34,238,239       2 8.0-9.0 8.0 C1 122 2009 2 10.2-41.9 41.9 B2 86 2009 1 13.4 13.4 C0 176 2012  
Pakistan240,241             2 6.0-37.0 6.0 C3 100 2013        
Thailand242-244       2 9.0-11.9 9.0 B2 416 2008       1 5.6 5.6 B2 215 2014  
Vietnam33,245,246              2 9.4-
16.3
16.3 A3 849 2009 1 13.2 13.2 C0 153 2014
Totala  6 8.3 8.3    12 3.6-9.2 5.9    10 12.9-17.6 16.3    5 6.7-13.3 10.6     
Asia Pacific & Australasia
Australia247-250                   4 3.4-6.3 4.9 B2 1719 2001  
Japan251-256       1 5.4 5.4 B2 166 2002       6 6.3-17.9 7.2 B3 817 2013  
South Korea257                   1 5 5.0 B0 541 2013  
Totala        1 5.4 5.4          11 4.9-7.2 5.0     
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 General Population Heterosexual and pregnant women PWID MSM
 Total studies Best estimate Total studies Best estimate Total studies Best estimate Total studies Best estimate
Country n Rangeb  % S n Year n Rangeb  % S n Year n Rangeb  % S n Year N Rangeb  % S n Year  
West, Central and East Europe
Belgium164,165                   3 0.0-6.1 6.1 B0 3081 2009  
Bulgaria166             1 16.9 16.9 B2 359 2011 1 9.7 9.7 B2 1087 2011  
Denmark                          
France167-171       2c  6.0-6.9 6.9 B0 6548 2013       2 5.0-8.8 8.8 B2 2351 2002  
Georgia                          
Germany169,172-174                   4 1.7-25.4 25.4 B3 1843 2012  
Greece175,176                   2 6.0-6.5 6.0 A2 1729 2003  
Ireland                          
Italy177,178             2 3.5-7.0 7.0 C2 173 2006        
Moldova             1 11.0 11.0 C3 113 2009        
Netherlands179-182       1c  4.9 4.9 B0 1546 2008       2 5.2-7.7 5.2 A2 12 800 2012  
Poland                          
Portugal183             1 4.1 4.1 C0 343 2005        
Romania                          
Spain184-188       1 2.3 2.3 B0 741 2006 1 3.9 3.9 B0 821 2015 4 4.3-10.9 4.3 B2 392 2011  
Serbia                          
Slovenia                          
Switzerland                          
Turkey189-191       2 7.1-11.4 11.4 C3 70 2007       1 4.0-4.0 4.0 B0 55 2009  
United Kingdom192,193                   2 2.1-5.3 5.3 A0 25 486 2012  
Ukraine                          
Totala        6 4.9-7.1 5.9    6 4.1-11.0 7.0    21 5.2-8.8 6.0     
East Asia
China34,194-199 1 0.4 0.4 C0 275 2017       5 1.1-59.6 11.8 B3 498 2014 1 14.2-14.2 14.2 B0 532 2010  
China, province of 
Taiwan200-217
      1 12.8 12.8 B2 105 2005 6 17.4-20.0 18.9 A2 301 2010 13 3.5-22.0 3.5 C3 523 2012  
Totala  1 0.4 0.4    1 12.8 12.8    11 11.8-18.9 15.4    14 3.5-14.2 8.8     
South and South-East Asia
Cambodia                          
India218-235 6 0.0-8.3 8.3 B2 121 2017 8 0.0-7.1 3.4 B2 3142 2012 2 11.9-12.9 12.9 B2 595 2014 2 3.2-7.9 7.9 B2 1178 2002  
Indonesia236,237             2 7.0-17.6 17.6 B3 74 2009        
Malaysia                          
Myanmar34,238,239       2 8.0-9.0 8.0 C1 122 2009 2 10.2-41.9 41.9 B2 86 2009 1 13.4 13.4 C0 176 2012  
Pakistan240,241             2 6.0-37.0 6.0 C3 100 2013        
Thailand242-244       2 9.0-11.9 9.0 B2 416 2008       1 5.6 5.6 B2 215 2014  
Vietnam33,245,246              2 9.4-
16.3
16.3 A3 849 2009 1 13.2 13.2 C0 153 2014
Totala  6 8.3 8.3    12 3.6-9.2 5.9    10 12.9-17.6 16.3    5 6.7-13.3 10.6     
Asia Pacific & Australasia
Australia247-250                   4 3.4-6.3 4.9 B2 1719 2001  
Japan251-256       1 5.4 5.4 B2 166 2002       6 6.3-17.9 7.2 B3 817 2013  
South Korea257                   1 5 5.0 B0 541 2013  
Totala        1 5.4 5.4          11 4.9-7.2 5.0     
(Continues)
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this population, there were 23 estimates for pregnant women from 
15 countries (see footnote to Table 1 for country-specific estimates). 
The mid-point prevalence of HBsAg co-infection among 67 studies in 
heterosexual PLHIV was 8.0% (IQR 5.0%-11.8%) compared to 4.6% 
(2.4%-5.9%) among PLHIV pregnant women (data not shown).
3.3.3 | People who inject drugs
The mid-point prevalence among PWID based on 36 studies was 11.8% 
(IQR 6.0%-16.9%) with country-level prevalence estimates shown in 
Figure 2C. The highest prevalence was observed in Latin America (27.3%, 
one study), South and South-East Asia (16.3%), East Asia (15.4%), and 
the lowest in North Africa and the Middle East (3.6%). Some single 
studies reported very high prevalence, including China (59.6%),34 Iran 
(44.2%)35 and Myanmar (41.9%).34 There was only one study from sub-
Saharan Africa (Kenya) which reported a prevalence of 13.9%.36
3.3.4 | Men who have sex with men
The mid-point prevalence among MSM was 6.1% (IQR 5.0%-9.2%) 
based on 70 studies with country-level prevalence estimates shown 
in Figure 2D. Prevalence was highest in South and South-East Asia 
(10.6%), West and Central Africa (9.2%, one study), followed by East 
Asia (8.8%) and Latin America (7.2%). Lower prevalences of around 
4%-6% were reported from Asia Pacific/Australasia, Europe and 
North America. There were no studies from East Africa, South Africa 
or North Africa and the Middle East.
3.3.5 | Other high-risk groups
In addition to the main HIV-exposure categories, there were 243 
estimates from samples of PLHIV engaging in mixed sexual and/or 
injecting risk behaviours (Table S3) with country-level prevalence 
estimates shown in Figure 2E. The point prevalence was 6.4% (IQR 
4.3%-9.6%) and was similar across the regions, except for East Asia 
(15.6%), and West and Central Africa (10.6%).
3.3.6 | Children and young people
There were 22 estimates of HIV-HBsAg co-infection among children 
and young people from 13 countries (Table S3). The mid-point preva-
lence was 6.8% (IQR 2.5-10.0). Prevalence ranged from 2% to 20% 
 General Population Heterosexual and pregnant women PWID MSM
 Total studies Best estimate Total studies Best estimate Total studies Best estimate Total studies Best estimate
Country n Rangeb  % S n Year n Rangeb  % S n Year n Rangeb  % S n Year N Rangeb  % S n Year  
Latin America (Central, South America & Caribbean)
Argentina                          
Brazil258-271 3 0.5-1.0 0.5 B2 186 2012 6c  0.5-3.3 2.3 C3 130 2008 1 27.3 27.3 B2 205 2003 5 2.9-31.0 8.2 B2 170 2000  
Chile272                   1 6.1 6.1 B0 395 2007  
Colombia273-275 1 1.2 1.2 C3 247 2009 2 2.9-3.3 3.3 B2 275 2010              
Ecuador276                   1 4.0 4.0 C0 50 2012  
Haiti277       1c  2.4 2.4 B3 123 2012              
Peru278                   1 9.5 9.5 B0 338 2003  
Venezuela279,280       2 3.1-11.8 3.1 C3 418 2008              
Totala  4 0.5-1.1 0.9    11 2.4-3.2 2.8    1 27.3 27.3    8 5.1-8.9 7.2     
North America
Canada154,281       1c  5.6 5.6 C0 142 2010       1 2.8 2.8 B2 294 2012  
USA282-291       1c  2.9 2.9 B2 1500 1995 1 7.0 7.0 C0 3987 2001 9 1.8-9.3 5.5 B2 816 2006  
Totala        2 2.9-5.6 4.2    1 7.0 7.0    10 2.8-5.5 4.2     
Global totala  45 1.4-15.7 7.4    90 3.4-11.0 6.1    36 6.0-16.9 11.8    70 5.0-9.2 6.1     
Abbreviation: S, Study quality score.
aTotals are derived from median of best estimates scored with interquartile range of best estimates. 
bRange is presented for country-level estimates and interquartile range for regional and global totals. All best estimates are selected according to  
the decision rules in Text Box S2. 
cDenotes prevalence (total) derived from samples of PLHIV pregnant women among the population group PLHIV (heterosexual and pregnant women)  
including: Cameroon (2) 9.3%,74 14.6%73; Cote D’Ivoire (1) 9.0%80; Nigeria (1) 4.2%105; South Africa (3) 6.2%,120 3.4%,118 2.1%117; Malawi (1) 8.7%141;  
Rwanda (1) 2.4%145; Tanzania (1) 6.2%147; Uganda (1) 4.9%145; Brazil (5) 1.9%,261 0.5%,266 2.3%,260 0.9%,262 1.2%268; USA (1) 2.9%290;  
Canada (1) 5.6%154; Haiti (1) 2.4%277; France (2) 6.0%,170 6.9%168; the Netherlands (1) 4.9%,180 and Morocco (1). 
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across six estimates from Nigeria37-42 and between 0% and 20.5% in 
South Africa.43-46 Extremely high prevalence (43%-46%) was observed in 
Romania in two studies47,48 where HIV infection was acquired nosocomi-
ally prior to 1995. A high prevalence (32.6%) was also found in Thailand 
among young people perinatally infected with HIV (mean age 14 years).49 
Prevalence was lower (~2%) among samples in India, Malawi, Poland, 
Spain and the United States,50-54 among HIV-positive paediatric patients. 
Prevalence was higher in Benin (9.6%), Rwanda (6.8%), Tanzania (7%) and 
Zambia (10.4%) among children <16 years recruited through HIV clin-
ics.48,55-57 HIV-exposure categories were not consistently reported.
3.3.7 | Odds of HBsAg positivity among PLHIV 
compared to HIV-negative persons
Overall, when we compared HBsAg estimates from 25 598 HIV-
positive with 286 121 HIV-negative individuals, we found increased 
odds for HBsAg positivity among all HIV-positive population 
groups compared to HIV-negative populations (OR = 1.42; 95% 
CI = 1.10-1.83) although there was a high degree of heterogeneity 
(I squared = 95.3%, P < .001). Odds of HBsAg were highest among 
HIV-positive children (OR = 4.61; 95% CI = 1.80-11.84), and there 
was a borderline statistically significant increase among MSM (2.69; 
95% CI 0.71-10.25), but not with other population groups. This is 
summarized in Figure 3 and Table S4.
3.3.8 | Global burden of HBV co-infection 
among PLHIV
Based on 2017 UNAIDS estimates of the number of PLHIV and PWID 
infected with HIV by region, we estimate that there are 2 653 300 
(IQR = 1 970 300-4 238 300) cases of HBsAg co-infection among PLHIV 
globally. Only 3% of cases (n = 142 000; IQR = 124 400-154 700) are 
among HIV-positive PWID. This equates to a global prevalence of HBsAg 
co-infection among PLHIV of 7.6% (IQR 5.6%-12.1%). Sub-Saharan 
Africa has the largest burden of HIV-HBsAg co-infection representing 
69% of the total number of cases, followed by South-East Asia (12%) 
and Latin America (6%). All other regions account for <5% each (Table 2).
4  | DISCUSSION
This is the first systematic review to provide global, regional and 
country estimates of prevalence and burden of HBsAg positivity 
among PLHIV across six population sub-groups; complementing 
 General Population Heterosexual and pregnant women PWID MSM
 Total studies Best estimate Total studies Best estimate Total studies Best estimate Total studies Best estimate
Country n Rangeb  % S n Year n Rangeb  % S n Year n Rangeb  % S n Year N Rangeb  % S n Year  
Latin America (Central, South America & Caribbean)
Argentina                          
Brazil258-271 3 0.5-1.0 0.5 B2 186 2012 6c  0.5-3.3 2.3 C3 130 2008 1 27.3 27.3 B2 205 2003 5 2.9-31.0 8.2 B2 170 2000  
Chile272                   1 6.1 6.1 B0 395 2007  
Colombia273-275 1 1.2 1.2 C3 247 2009 2 2.9-3.3 3.3 B2 275 2010              
Ecuador276                   1 4.0 4.0 C0 50 2012  
Haiti277       1c  2.4 2.4 B3 123 2012              
Peru278                   1 9.5 9.5 B0 338 2003  
Venezuela279,280       2 3.1-11.8 3.1 C3 418 2008              
Totala  4 0.5-1.1 0.9    11 2.4-3.2 2.8    1 27.3 27.3    8 5.1-8.9 7.2     
North America
Canada154,281       1c  5.6 5.6 C0 142 2010       1 2.8 2.8 B2 294 2012  
USA282-291       1c  2.9 2.9 B2 1500 1995 1 7.0 7.0 C0 3987 2001 9 1.8-9.3 5.5 B2 816 2006  
Totala        2 2.9-5.6 4.2    1 7.0 7.0    10 2.8-5.5 4.2     
Global totala  45 1.4-15.7 7.4    90 3.4-11.0 6.1    36 6.0-16.9 11.8    70 5.0-9.2 6.1     
Abbreviation: S, Study quality score.
aTotals are derived from median of best estimates scored with interquartile range of best estimates. 
bRange is presented for country-level estimates and interquartile range for regional and global totals. All best estimates are selected according to  
the decision rules in Text Box S2. 
cDenotes prevalence (total) derived from samples of PLHIV pregnant women among the population group PLHIV (heterosexual and pregnant women)  
including: Cameroon (2) 9.3%,74 14.6%73; Cote D’Ivoire (1) 9.0%80; Nigeria (1) 4.2%105; South Africa (3) 6.2%,120 3.4%,118 2.1%117; Malawi (1) 8.7%141;  
Rwanda (1) 2.4%145; Tanzania (1) 6.2%147; Uganda (1) 4.9%145; Brazil (5) 1.9%,261 0.5%,266 2.3%,260 0.9%,262 1.2%268; USA (1) 2.9%290;  
Canada (1) 5.6%154; Haiti (1) 2.4%277; France (2) 6.0%,170 6.9%168; the Netherlands (1) 4.9%,180 and Morocco (1). 
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a companion review on HIV-HCV antibody co-infection.27 We es-
timate a global prevalence of 7.6% (IQR 5.6%-12.1%) or 2.7 million 
(IQR 2.0-4.2 million) cases of HIV-HBsAg co-infection. The great-
est burden (69% of all cases; 1.9 million) is in sub-Saharan Africa 
where there is the largest number of PLHIV. This is followed by 12% 
(355 600) in South and South-East Asia and 6% (68 800) in Latin 
America.
HBsAg prevalence was broadly similar across different HIV-
positive population groups, with a prevalence of 6%-7% reported 
among general population samples, heterosexually exposed or 
pregnant women, children, MSM and high-risk populations. Only 
among PWID was prevalence higher at 11.8%. PWID accounted for 
only 3% of the global co-infected population, but a much higher 
proportion in Eastern Europe (45% of cases). We were limited in our 
ability to make regional comparisons across sub-populations be-
cause only two regions (sub-Saharan Africa and South and South-
East Asia) had general population data, and there were little data 
among high-risk populations in sub-Saharan Africa. The most com-
prehensive data from different regions was among heterosexual or 
pregnant PLHIV. The prevalence was highest in West and Central 
Africa (12.0%), and East Asia (12.8%) and lowest in Latin America 
(2.8%) and North America (4.2%).
Our global estimate of burden of HIV-HBsAg co-infection is 
broadly consistent with previous estimates of 2-4 million.24,25,58,59 
A review of HIV-HBsAg co-infection in sub-Saharan Africa found 
a mean prevalence of 12.5% among HIV-positive cohorts, slightly 
higher than we found, although that study did not disaggregate by 
HIV-exposure category making comparisons challenging.25 Our find-
ings broadly reflect existing data on the main routes of transmission 
of HBV infection. In sub-Saharan Africa, HBV infection is predomi-
nantly acquired perinatally or in early childhood, leading to high rates 
of chronic infection.4,60 The contribution of adult acquisition is low, 
as the majority are already chronically infected or immune. As a re-
sult, most people have already been HBV-infected for many years by 
the time they are exposed to HIV in adulthood, which may explain 
why the prevalence is similar across different sub-populations.9 In 
contrast, in other regions a higher prevalence occurs among PWID 
and MSM compared to the general population. This was particularly 
marked in Latin America, with co-infection prevalence of 9.5% and 
27% among PWID and MSM, respectively, compared to 0.9% in the 
general population. This is consistent with co-transmission of HBV 
and HIV in adulthood in these settings, with much lower transmission 
of HBV in childhood.22 A significant proportion of cases in high risk 
populations may also represent acute infection, which will not lead to 
chronic infection.
This HIV-HBsAg review and a companion review of HIV-HCV 
antibody co-infection (consistent with past or current infection)27 
highlights important differences between the epidemiology of these 
co-infections. Although the global prevalence and burden are similar 
(7.6% for HIV-HBsAg compared to 6.2% for HIV-HCV) antibody, al-
most three-quarters of the global burden of HIV-HBsAg co-infection 
in 2017 is in sub-Saharan Africa (1.91 million), 4-5 times as many as 
HIV-HCV co-infections (429 600). In contrast, the greatest burden 
of HIV-HCV co-infection is in the concentrated epidemic settings of 
Central Asia and Eastern Europe among PWID, accounting for 27% 
of the HIV-HCV burden (607 700). There is a much lower prevalence 
of HBsAg than HCV antibody among HIV-positive PWID (11.8% vs 
82%), accounting for 3% (142 000) of HIV-HBsAg co-infections but 
59% (1.36 million) of HIV-HCV co-infections. Overall, we found less 
variability in HIV-HBsAg prevalence between sub-populations, and 
HIV infection was a less important risk factor for HBsAg positivity 
than for HCV antibody positivity.
F I G U R E  3   Forest plot showing meta-
analysis of odds of HBsAg infection in 
HIV-positive populations versus HIV-
negative populations
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Key strengths of our systematic review were the comprehensive 
search of published literature in English, French, Russian, Chinese, 
Portuguese, Arabic and Spanish; the stratification of co-infection es-
timates for different population sub-groups; and the large number 
of studies among heterosexually exposed and pregnant women liv-
ing with HIV—the main source for regional estimates of HIV-HBsAg 
co-infection. Despite this, estimates were available for only 41% of 
countries, half being in sub-Saharan Africa. Five regional prevalence 
estimates for different sub-populations were based on data from a 
single country, possibly unrepresentative of the true regional profile. 
Few countries had data for all sub-populations making regional com-
parisons difficult. We excluded studies that only presented region-
al-level data, not disaggregated by country, to enable us to observe 
how prevalence varied by country and risk group within a region and 
to take account of the differing epidemiology of HIV at a country level. 
However, this resulted in the exclusion of large cohorts that aggre-
gate across country and region. One major cohort that reports data 
across Europe, Israel and Argentina found a comparable prevalence 
of HIV-HBsAg co-infection (7.1%-8.7%) with similar high prevalence 
observed in Argentina among PLHIV (exposure group not specified) to 
the range of prevalence we found among MSM.61,62
The quality of studies was also variable. Few studies were based 
on large multisite surveys, with 40% of sero-surveys being based on 
data from one city and fewer than 200 persons. In addition, over 
half of studies provided no details of the assay type and testing pro-
tocol; with much of the remainder using a recent HBsAg assay but 
without confirmatory HBsAg testing, possibly overestimating the in-
fected population. In general, WHO does not recommend the use of 
a second confirmatory HBsAg assay for diagnosis of CHB infection 
(23). We also did not exclude populations based on receiving ART, 
with few studies reporting the prevalence of ART making it difficult 
to adjust for the effects of treatment. The use of tenofovir-based 
ART regimens may have reduced detection of HBsAg among some 
samples.63 Finally, we have not taken into account increases in both 
ART coverage and the use of tenofovir-based ART regimens that may 
result in lower levels of co-infection in later years.
Our findings have important programmatic implications. First, 
universal infant and perinatal HBV vaccination remains the key 
strategy for preventing mother-to-child transmission and con-
trolling the HBV epidemic. Although high uptake of infant vac-
cination has been achieved, leading to substantial decreases in 
incidence in recent years, HBV birth-dose vaccination is being 
implemented by less than half of countries, and only 9/48 of 
countries in Africa.4 Rates of adult vaccination also remain low, 
with <3% of countries routinely vaccinating high-risk populations 
(PWID, MSM, sex workers and prisoners).22 Our findings highlight 
the importance of targeting PLHIV, especially high-risk groups and 
children for testing, catch-up HBV vaccination and other preven-
tative interventions.64 Second, the global scale-up of HIV treat-
ment for PLHIV using a tenofovir-based ART regimen represents 
a major opportunity for achieving global targets towards hepati-
tis B elimination in PLHIV, by simultaneously treating those who 
have chronic and HIV co-infection so reducing mother-to-child 
transmission of HBV alongside HIV.65 ART coverage is now ap-
proximately 50% in most countries and encouragingly coverage 
in eastern and southern Africa is higher than the global aver-
age,66 with 60% of persons on ART receiving a tenofovir-based 
regimen.67 Our findings clearly show the need to scale-up teno-
fovir-based ART to address HIV-HBsAg co-infection, particularly 
focusing on sub-Saharan Africa.
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